about
Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans.Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor.MicroRNA-mediated suppression of oncolytic adenovirus replication in human liverIncomplete but infectious vaccinia virions are produced in the absence of oncolysis in feline SCCF1 cells.Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumorsMicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic AdenovirusSafety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory BeaglesOvercoming tumor resistance by heterologous adeno-poxvirus combination therapy.Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.Cancer-targeted oncolytic adenoviruses for modulation of the immune system.Interferon-β sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models.Replication competent Semliki Forest virus prolongs survival in experimental lung cancer.Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas.Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.Oncolytic adenoviruses: A potent form of tumor immunovirotherapyGMCSF-armed vaccinia virus induces an antitumor immune response.Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.Propagation, purification, and in vivo testing of oncolytic vesicular stomatitis virus strains.Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2.Oncolytic adenovirus improves anti-tumor efficacy of adoptive T cell therapy by breaking tumor-induced immunosuppression and peripheral tolerance.Corrigendum to "Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma".Tumor Restrictions to Oncolytic Virus.PROX1 is a transcriptional regulator of MMP14.Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles
P50
Q30571240-6B8E5F88-CA41-4E42-8A15-B085DEACDE02Q33931640-969C8520-0937-4586-9AAB-17A720DF3539Q34426949-3F8E3E5B-F610-4B4C-9856-26FCAA58419CQ34476462-7E0DE527-12B8-486B-A7ED-AD746CD50344Q34563212-0AFE0CF4-828B-4C4B-BF11-121140C896D2Q35584276-2715D22B-5315-4CFF-8DB2-482799C3DFDEQ35673240-2DF9EC39-F7BD-4B89-B552-7230A30C8799Q36086370-B9C8F1B4-5AE3-45C4-9BCD-D2DBF180DBB0Q36582785-57AC8676-E3B8-418D-ACF3-66872E78749CQ36664201-FC44B369-2AF2-4BC5-891A-9F9B8ED473E9Q36664229-02B160D3-3F3E-49AA-B7F1-8514A45DAF5AQ38772099-6B020D81-F4F4-44D7-B193-76872CD17CF0Q38893420-3CF7F5B9-746F-47D9-B4F2-6A1626636480Q39278811-D4B5E553-A9C5-4015-BFB4-D7779B0C4D2CQ39376227-C0F64123-B6CD-4DA7-AA78-0A6C16E0B6A6Q39957846-9785EA92-9269-4FDA-B184-BA03DE75F8D1Q40086745-B09E816A-5229-4B21-A3B9-2495AAB6581AQ40143926-7C32F6BF-A8F0-4AD5-AE19-A845411F3E82Q40542181-8157ECE1-2F13-450F-96A4-C06EE26469ABQ40674940-E5BCB936-D98E-424E-9779-D0F5FC492FB1Q41474598-C31734B7-FE68-43D1-9E26-587901D6DF08Q42205083-A407C0FB-99D9-45B1-9B70-5F112A100AC0Q42695310-BC43A309-8FA4-454A-96B0-8A1793582DC0Q45363006-33741D88-891C-4D5E-8475-98C32676F677Q45893913-2678B4D0-9CBF-4F02-9F7D-AF5F42101A53Q45906960-C64E2B77-46BE-4EE2-8D16-A9BF0C3970C4Q47146510-7FAEB542-6BA8-4783-BE3E-55B6924391DAQ51846287-6297CFC2-A3EF-4424-A69E-679D0A92BC19Q55472285-38823987-9D6A-47B6-A6CD-7F34548988F2Q58743052-B017ADB8-B6FB-4A5B-9B1B-F167AD44F3BA
P50
description
onderzoeker
@nl
name
Markus Vähä-Koskela
@ast
Markus Vähä-Koskela
@en
Markus Vähä-Koskela
@nl
Markus Vähä-Koskela
@sl
type
label
Markus Vähä-Koskela
@ast
Markus Vähä-Koskela
@en
Markus Vähä-Koskela
@nl
Markus Vähä-Koskela
@sl
prefLabel
Markus Vähä-Koskela
@ast
Markus Vähä-Koskela
@en
Markus Vähä-Koskela
@nl
Markus Vähä-Koskela
@sl